September 30, 2011
Emerald BioStructures, Deciphera Pharmaceuticals Continue Allosteric Kinase Inhibitor Collaboration
Bainbridge Island, WA. September 30, 2011. Deciphera Pharmaceuticals LLC (Lawrence, Kansas) has renewed an agreement with Emerald BioStructures, Inc. to elucidate the X-ray co-crystal structures of novel “Switch Pocket Inhibitors” bound to kinase targets implicated in tumor growth and autoimmune diseases. Emerald and Deciphera have had a longstanding collaboration which has resulted in the atomic resolution structure determination of more than 100 effectors bound kinase co-crystal structures. This fee based and milestone project will utilize Emerald’s Crystal Ready™ kinase and high throughput crystallization platforms.
About Emerald BioStructures
Emerald BioStructures is an integrated gene-to-structure contract research organization that provides collaborative drug discovery services to pharmaceutical companies, biotechnology companies, academic institutions, and government facilities. The company operates a high-throughput platform leveraged for fragment-based lead discovery, structure-based drug design, and elucidation of antibody-antigen structures. Emerald’s work provides a solid foundation for the discovery of highly selective, efficacious drugs. www.emeraldbiostructures.com
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, LLC was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce “best-in-class” small molecule Switch Inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform, Phylomechanics. www.deciphera.com
Emerald BioStructures Contact:
Emerald BioStructures: Diana Wetmore, VP of Business Development & Alliances (206) 780-8959, dwetmore@embios.com
Deciphera Pharmaceuticals Contact:
Daniel Flynn, CEO, (785) 830-2100, dflynn@deciphera.com